U.S. Markets open in 2 hrs 38 mins
  • S&P Futures

    4,162.75
    -28.75 (-0.69%)
     
  • Dow Futures

    34,030.00
    -67.00 (-0.20%)
     
  • Nasdaq Futures

    12,681.00
    -165.75 (-1.29%)
     
  • Russell 2000 Futures

    2,006.90
    -1.00 (-0.05%)
     
  • Crude Oil

    75.78
    -0.10 (-0.13%)
     
  • Gold

    1,926.00
    -4.80 (-0.25%)
     
  • Silver

    23.52
    -0.09 (-0.38%)
     
  • EUR/USD

    1.0929
    +0.0018 (+0.1639%)
     
  • 10-Yr Bond

    3.3960
    0.0000 (0.00%)
     
  • Vix

    18.44
    +0.57 (+3.19%)
     
  • GBP/USD

    1.2257
    +0.0028 (+0.2280%)
     
  • USD/JPY

    128.4030
    -0.2010 (-0.1563%)
     
  • BTC-USD

    23,513.30
    -324.78 (-1.36%)
     
  • CMC Crypto 200

    536.90
    -8.41 (-1.54%)
     
  • FTSE 100

    7,836.42
    +16.26 (+0.21%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission

  • Clover Biopharmaceuticals Ltd announced that Clinical Infectious Diseases has published additional data from the SPECTRA Phase 2/3 trial that showed the SCB-2019 COVID-19 vaccine reduced the risk of transmission to household members compared to placebo participants.

  • Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax Technologies Corp's (NASDAQ: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

  • The study demonstrated that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 compared to households where the infected household member was not vaccinated.

  • Related: China-Based COVID-19 Shot Neutralizes Omicron Subvariants.

  • Among the 134 household contacts of infected household members who had received SCB-2019, there was one COVID-19 case; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.

  • No cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019.

  • Clover is working towards completing regulatory submissions in China, Europe, and the World Health Organization for SCB-2019 by the end of 2022.

  • Price Action: DVAX shares closed at $11.88 on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.